Loading
Ardelyx, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 23 Feb 2026.
Ardelyx, Inc.: what insiders have been doing
Every trade that managers of Ardelyx, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. The last twelve months, up to 18 October 2026, brought 96 filings signed by 26 insiders.
Purchases and sales both appear in the filings: 1 purchase (1 insider, €1.7M) and 59 sales (9 insiders, €2.3M). No amount is published for 2 filings, which the totals therefore leave out. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The largest single trade was a purchase of €1.7M by Mott David M, published on 23 February 2026. Those buying include 1 senior executive.
The most recent open-market purchase was published on 23 February 2026, 237 days ago. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 96 filings, this issuer sits above that mark. Looking back to 2016, when coverage begins, insiders filed 47 purchases and 235 sales. The 10-K for the year ended 31 December 2025 shows 407.3 m USD of revenue and -61.6 m USD of net income.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
409
Thresholds
n/a
Buy Volume
€9M
47 ops. · all time
Sell Volume
€11M
235 ops. · all time
Who traded when
BuySaleMichael Raab21 sales
Laura A. Williams15 sales
Eric Duane Foster10 sales
Mike Kelliher10 sales
Mott David M9 buys
Joseph James Reilly6 sales
+7 other insiders
Since the insiders bought
- -4.7%Entry US$6.56 · Close at T+90 US$6.25
- +321.1%Entry US$1.09 · Close at T+365 US$4.59
- +321.1%Entry US$1.09 · Close at T+365 US$4.59
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Ardelyx, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$12.90.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,900 of 24,148 companies
28.9
score / 100
Value20
Quality38
FCF yld-5.5%
Earn yld-7.7%
EV/EBITDA·
ROE-39%
Gross mgn90%
Net mgn-15%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.09
Analyst consensus
10 analystsStrong buy
US$8.00Target US$12.90(+317%)US$18.00
Income statement
RevenueUS$407.3M
Gross profitUS$367.8M90% margin
EBITDA-US$29.2M-7% margin
Net income-US$61.6M-12.4% margin
Valuation
PER (forward)10.6x
P/Book5.2x
Beta0.68
Balance sheet & cash
Market capUS$797.8M
Total debtUS$208M
Free Cash Flow-US$44M
Debt / Equity190%
Profitability & ownership
ROE-38.6%
ROA-4.3%
% insiders3.0%
% institutions73.2%
Last declaration on 25 August 2026
Declarations409 total
3,389 shares@ US$3.85690.0014% mcap4.1% of flowCommon StockSEC:0002034148-26-000007:1
2,575 shares@ US$3.85690.0011% mcap3.1% of flowCommon StockSEC:0002034148-26-000007:2
17,281 shares@ US$3.85690.0073% mcap31.8% of flowCommon StockSEC:0001308911-26-000007:0
2,469 shares@ US$3.85690.0010% mcap4.5% of flowCommon StockSEC:0001308911-26-000007:1
15,009 shares@ US$3.85690.0064% mcap1.1% of flowCommon StockSEC:0001321402-26-000019:0
15,976 shares@ US$3.85690.0068% mcap1.2% of flowCommon StockSEC:0001321402-26-000019:1
8,411 shares@ US$3.85690.0036% mcap0.6% of flowCommon StockSEC:0001321402-26-000019:2
19,178 shares@ US$3.85690.0082% mcap1.4% of flowCommon StockSEC:0001321402-26-000019:3
3,486 shares@ US$3.85690.0015% mcap0.9% of flowCommon StockSEC:0001869194-26-000011:0
3,089 shares@ US$3.85690.0013% mcap0.8% of flowCommon StockSEC:0001869194-26-000011:1
2,430 shares@ US$3.85690.0010% mcap0.6% of flowCommon StockSEC:0001869194-26-000011:2
1,734 shares@ US$3.85690.0007% mcap0.4% of flowCommon StockSEC:0001869194-26-000011:3
3,104 shares@ US$3.85690.0013% mcap4.1% of flowCommon StockSEC:0001987188-26-000009:0
2,652 shares@ US$3.85690.0011% mcap3.5% of flowCommon StockSEC:0001987188-26-000009:1
2,002 shares@ US$3.85690.0009% mcap2.6% of flowCommon StockSEC:0001987188-26-000009:2
2,598 shares@ US$3.85690.0011% mcap3.1% of flowCommon StockSEC:0002034148-26-000007:0
2,872 shares@ US$3.85690.0012% mcap7.6% of flowCommon StockSEC:0002044416-26-000008:0
1,110 shares@ US$3.85690.0005% mcap2.9% of flowCommon StockSEC:0002044416-26-000008:1
1,976 shares@ US$3.85690.0008% mcap4.7% of flowCommon StockSEC:0002088887-26-000007:0
13,160 shares@ US$3.85690.0056% mcap31.2% of flowCommon StockSEC:0002088887-26-000007:1
1,558 shares@ US$3.85690.0007% mcap16.6% of flowCommon StockSEC:0002093095-26-000007:0
25,500 shares@ US$4.030.011% mcap49.0% of flowCommon StockSEC144:0001308911-26-000005
44,500 shares@ US$4.030.020% mcap3.4% of flowCommon StockSEC144:0001321402-26-000017
10,500 shares@ US$4.030.0047% mcap2.8% of flowCommon StockSEC144:0001869194-26-000009
10,500 shares@ US$4.030.0047% mcap14.5% of flowCommon StockSEC144:0001987188-26-000007
25 of 409 declarations
About Ardelyx, Inc.
Ardelyx, Inc. (ticker: ARDX) is a U.S.-listed biopharmaceutical company traded on the Nasdaq market in the United States. Headquartered in Waltham, Massachusetts, it was founded in October 2007 as Nteryx and later renamed Ardelyx in June 2008. The company’s core business is the discovery, development, and commercialization of innovative medicines aimed at significant unmet medical needs. From an equity research perspective, Ardelyx should be viewed as a commercial-stage biotech rather than a pure development-stage platform, because it already generates product revenue and is executing a direct commercialization strategy in the U.S.
Ardelyx’s business model is centered on two approved products in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor). IBSRELA is marketed for adults with irritable bowel syndrome with constipation (IBS-C), while XPHOZAH is used in the treatment of hyperphosphatemia in adults with chronic kidney disease on dialysis. Both products are based on tenapanor and reflect Ardelyx’s differentiated scientific platform, which targets NHE3 inhibition. This gives the company a focused therapeutic profile spanning gastroenterology and nephrology, with a clinically distinct mechanism that supports its positioning versus broader-capability large-cap pharmaceutical peers.
Read moreShow less
In competitive terms, Ardelyx remains a relatively specialized mid-cap player in a market dominated by larger pharmaceutical and biotech companies with deeper sales infrastructure and more diversified portfolios. Its key competitive strengths are the first-in-class nature of its assets, the commercial momentum of IBSRELA, and the continued market adoption of XPHOZAH. The company’s revenue base is currently concentrated in the United States, which makes its growth profile highly dependent on domestic commercialization execution, payer access, physician uptake, and ongoing product differentiation.
Recent developments have reinforced the company’s growth narrative. Ardelyx reported strong commercial progress in 2025, including continued IBSRELA growth and increasing XPHOZAH adoption. In early 2026, management updated the strategic outlook and highlighted a new Phase 3 program for IBSRELA in chronic idiopathic constipation, as well as work on a next-generation NHE3 inhibitor, RDX10531. The company also made leadership changes during 2025, signaling an emphasis on execution, pipeline expansion, and long-term operational discipline. For investors following Nasdaq-listed healthcare names, Ardelyx offers a combination of commercial-stage revenue growth, pipeline optionality, and therapeutic specialization within the United States biopharma landscape.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
